Donanemab + Placebo

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Down Syndrome (DS)

Conditions

Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease, Amyloid Beta Protein

Trial Timeline

Aug 1, 2026 → Dec 31, 2028

NCT ID

NCT06911944

About Donanemab + Placebo

Donanemab + Placebo is a approved stage product being developed by Eli Lilly for Down Syndrome (DS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06911944. Target conditions include Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease.

What happened to similar drugs?

0 of 2 similar drugs in Down Syndrome (DS) were approved

Approved (0) Terminated (2) Active (0)

❌Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + PlaceboEisaiPhase 3

❌Aricept (Donepezil hydrochloride) + PlaceboEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06911944	Approved	Recruiting	Aug 1, 2026	Dec 31, 2028	Down Syndrome (DS)
NCT05508789	Phase 3	Recruiting	Oct 10, 2022	Jul 1, 2028	Alzheimer Disease
NCT05533411	Phase 1	Completed	Sep 14, 2022	Jan 5, 2023	Healthy
NCT05026866	Phase 3	Active	Aug 27, 2021	Nov 1, 2027	Alzheimer Disease
NCT04437511	Phase 3	Active	Jun 19, 2020	Nov 1, 2028	Alzheimer Disease

Competing Products

13 competing products in Down Syndrome (DS)

See all competitors

Product	Company	Stage	Hype Score
Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)	Yuhan	Phase 1	29
Aricept (donepezil hydrochloride) + Aricept (donepezil hydrochloride) + Placebo	Eisai	Phase 3	32
Aricept (Donepezil hydrochloride) + Placebo	Eisai	Phase 3	32
Donepezil hydrochloride (Aricept)	Eisai	Phase 2	27
E2020-Donepezil hydrochloride + E2020-Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
Donepezil HCl + Placebo	Eisai	Phase 2	35
Placebo + RG1662	Roche	Phase 1	29
Placebo + RG1662 + RG1662	Roche	Phase 2	35
Placebo + RO5186582	Roche	Phase 2	27
RG1662 + placebo	Roche	Phase 1	29
ELND005 + Placebo	Elanco	Phase 2	32
ACI-24 low dose + ACI-24 high dose + Placebo	AC Immune	Phase 1	19
ACI-24 + Placebo	AC Immune	Phase 2	17